problems with glp 1 drugs If GLP-1 Are Good For Everything, Should We All Be on Them? GLP-1 Medications Infographic | Medidex

A review in Diabetes Technology & Therapeutics concluded that while some studies showed small benefits, results were inconsistent across trials

Those on semaglutide 2.4 mg weekly had a 20% lower relative risk of major cardiovascular events, including heart attack and stroke, over a median follow-up of nearly 40 months

Preprint at bioRxiv (2020)

Risk of hepatocellular carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis

Real-world evidence (RWE) was a major contributor in uncovering some of these unexpected benefits

Joshi GP, Abdelmalak BB, Weigel WA, Harbell MW, Kuo CI, Soriano SG, et al